Neuroendocrine Tumor – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NETs for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s NETs forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NETs over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts the following NET patient populations:

  • Diagnosed incident cases of NETs.
  • Diagnosed incident cases of lung NETs.
  • Diagnosed incident cases of gastroenteropancreatic NETs (GEP-NETs).
  • Diagnosed prevalent cases of NETs.
  • Diagnosed prevalent cases of lung NETs.
  • Diagnosed prevalent cases of GEP-NETs.
  • Diagnosed incident cases of nonmetastatic NETs.
  • Diagnosed incident cases of metastatic NETs.
  • … and many more (details available on request).

Note: Coverage may vary by country.